Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Timber Pharmaceuticals Inc (TMBR) USD0.001

Sell:$0.86 Buy:$0.93 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.86
Buy:$0.93
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.86
Buy:$0.93
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Timber Pharmaceuticals, Inc. (Timber) is a clinical-stage biopharmaceutical company. It is focused on development of treatments for orphan dermatologic diseases. It Is also focused on developing non-systemic treatments for dermatologic diseases, including congenital ichthyosis, facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. The Company's pipeline programs include TMB-001, TMB-002 and TMB-003. TMB-001 is topical formulation of isotretinoin, evaluated in a Phase II b clinical trial for the treatment of congenital ichthyosis (CI), a genetic keratinization. TMB-002 is a topical formulation of rapamycin, evaluated in a Phase II b clinical trial for the treatment of FAs in TSC, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. TMB-003 is a formulation of sitaxsentan in the preclinical development for the treatment of scleroderma, a rare connective tissue disorder characterized by abnormal thickening of the skin.

Contact details

Address:
110 ALLEN ROAD, SUITE 401
BASKING RIDGE
07920
United States
Telephone:
+1 (914) 2053481
Website:
https://www.timberpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TMBR
ISIN:
US8870801094
Market cap:
$32.64 million
Shares in issue:
36.66 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Koconis
    Chief Executive Officer, Director
  • Joseph Lucchese
    Chief Financial Officer, Executive Vice President
  • Zachary Rome
    Chief Operating Officer, Executive Vice President, Secretary, Director
  • Joyce Goto
    Chief Accounting Officer
  • Alan Mendelsohn
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.